Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$22.41 -2.4%	$20.79	$14.40 ▼ $47.00	$1.52B	1.13	967,013 shs	880,629 shs
DVAX Dynavax Technologies	$10.72 +0.5%	$10.10	$9.22 ▼ $14.63	$1.28B	1.03	2.14 million shs	928,420 shs
EBS Emergent Biosolutions	$6.94 -4.7%	$6.57	$4.02 ▼ $15.10	$395.14M	2.09	1.66 million shs	677,069 shs
JNJ Johnson & Johnson	$163.65 +0.4%	$154.10	$140.68 ▼ $169.99	$392.14B	0.41	8.14 million shs	9.76 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-0.04%	+1.28%	+14.51%	+25.52%	-40.77%
DVAX Dynavax Technologies	0.00%	-2.11%	+6.81%	+3.62%	0.00%
EBS Emergent Biosolutions	+4.27%	-0.61%	+16.84%	+57.85%	-39.44%
JNJ Johnson & Johnson	-1.06%	+3.38%	+6.99%	+3.57%	+4.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	2.4468 of 5 stars	4.4	1.0	0.0	0.0	3.6	0.0	0.0
DVAX Dynavax Technologies	4.3943 of 5 stars	3.3	2.0	0.0	4.7	2.3	1.7	1.9
EBS Emergent Biosolutions	4.1562 of 5 stars	3.5	1.0	0.0	4.6	1.4	2.5	1.3
JNJ Johnson & Johnson	4.7879 of 5 stars	2.3	4.0	4.2	3.9	3.4	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	123.61% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	123.88% Upside
EBS Emergent Biosolutions	3.00	Buy	$14.33	106.53% Upside
JNJ Johnson & Johnson	2.57	Moderate Buy	$172.87	5.63% Upside

Current Analyst Ratings Breakdown

Latest EBS, JNJ, CLDX, and DVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	JNJ Johnson & Johnson	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
7/17/2025	JNJ Johnson & Johnson	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$165.00 ➝ $176.00
7/17/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$181.00 ➝ $185.00
7/17/2025	JNJ Johnson & Johnson	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $190.00
7/17/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$164.00 ➝ $167.00
7/17/2025	JNJ Johnson & Johnson	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$161.00 ➝ $175.00
7/17/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$171.00 ➝ $176.00
7/10/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform
7/10/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$169.00 ➝ $171.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/5/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.02M	211.91	N/A	N/A	$11.26 per share	1.99
DVAX Dynavax Technologies	$277.25M	4.64	$0.16 per share	67.38	$4.54 per share	2.36
EBS Emergent Biosolutions	$1.04B	0.36	$1.91 per share	3.64	$8.91 per share	0.78
JNJ Johnson & Johnson	$88.82B	4.43	$13.03 per share	12.56	$29.69 per share	5.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
DVAX Dynavax Technologies	$27.31M	-$0.52	N/A	21.88	N/A	-20.39%	3.59%	2.20%	8/5/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.35	N/A	-13.63%	-0.52%	-0.17%	8/6/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$9.35	17.50	14.78	2.21	25.00%	33.07%	13.16%	N/A

Latest EBS, JNJ, CLDX, and DVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CLDX Celldex Therapeutics	-$0.86	N/A	N/A	N/A	$1.13 million	N/A
8/6/2025	Q2 2025	EBS Emergent Biosolutions	$0.21	N/A	N/A	N/A	$148.55 million	N/A
8/5/2025	Q2 2025	DVAX Dynavax Technologies	$0.12	N/A	N/A	N/A	$87.55 million	N/A
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	3.18%	N/A	55.61%	64 Years

Latest EBS, JNJ, CLDX, and DVAX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	21.67	21.67
DVAX Dynavax Technologies	0.49	11.93	10.84
EBS Emergent Biosolutions	1.20	6.32	3.51
JNJ Johnson & Johnson	0.49	1.26	1.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
DVAX Dynavax Technologies	96.96%
EBS Emergent Biosolutions	78.40%
JNJ Johnson & Johnson	69.55%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	4.40%
DVAX Dynavax Technologies	2.98%
EBS Emergent Biosolutions	1.20%
JNJ Johnson & Johnson	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
DVAX Dynavax Technologies	350	120.08 million	116.50 million	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	53.63 million	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable

EBS, JNJ, CLDX, and DVAX Headlines

Recent News About These Companies

Insider Sell: John Reed Sells Shares of Johnson & Johnson

3 hours ago | gurufocus.com

J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?

July 18 at 12:10 PM | zacks.com

Watch These Johnson & Johnson Price Levels After Stock's Post-Earnings Pop

July 18 at 11:11 AM | msn.com

Goldman Sachs Reaffirms Conviction Buy on Johnson & Johnson (JNJ) Before Q2 Earnings

July 18 at 11:11 AM | msn.com

Equities Analysts Offer Predictions for JNJ Q3 Earnings

July 18 at 10:03 AM | marketbeat.com

Creekmur Asset Management LLC Purchases 12,019 Shares of Johnson & Johnson (NYSE:JNJ)

July 18 at 9:44 AM | marketbeat.com

Burling Wealth Partners LLC Has $3.82 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

July 18 at 9:08 AM | marketbeat.com

Johnson & Johnson (NYSE:JNJ) Stake Lessened by Forte Capital LLC ADV

July 18 at 9:00 AM | marketbeat.com

Johnson & Johnson (NYSE:JNJ) Stock Holdings Boosted by Pzena Investment Management LLC

July 18 at 9:00 AM | marketbeat.com

Commerzbank Aktiengesellschaft FI Decreases Stock Position in Johnson & Johnson (NYSE:JNJ)

July 18 at 8:56 AM | marketbeat.com

Cooke & Bieler LP Sells 5,916 Shares of Johnson & Johnson (NYSE:JNJ)

July 18 at 8:52 AM | marketbeat.com

Johnson & Johnson (NYSE:JNJ) Shares Sold by Pettee Investors Inc.

July 18 at 8:51 AM | marketbeat.com

Johnson & Johnson (NYSE:JNJ) Shares Sold by Asset Advisors Investment Management LLC

July 18 at 8:48 AM | marketbeat.com

Fortis Group Advisors LLC Has $145,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

July 18 at 8:47 AM | marketbeat.com

Easterly Investment Partners LLC Buys 25,211 Shares of Johnson & Johnson (NYSE:JNJ)

July 18 at 8:46 AM | marketbeat.com

1,911 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by Kooman & Associates

July 18 at 8:45 AM | marketbeat.com

Kingsview Wealth Management LLC Trims Holdings in Johnson & Johnson (NYSE:JNJ)

July 18 at 8:44 AM | marketbeat.com

Guggenheim Maintained a Hold Rating on Johnson & Johnson (JNJ)

July 18 at 5:29 AM | insidermonkey.com

Hot or Not, Stock Market Edition: 07/18/2025

July 18 at 3:28 AM | wallstreetzen.com

Johnson & Johnson (NYSE:JNJ) Trading Up 5.4% After Better-Than-Expected Earnings

July 18 at 2:55 AM | americanbankingnews.com

JNJ gave us a manual on how to spot a stock that can soar after earnings, says Jim Cramer

July 17 at 8:14 PM | youtube.comY

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Want Steady Income? 3 Top Dividend Stocks for July 2025
By Chris Markoch | July 17, 2025
View Want Steady Income? 3 Top Dividend Stocks for July 2025
JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now
By Thomas Hughes | July 16, 2025
View JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now

EBS, JNJ, CLDX, and DVAX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$22.41 -0.56 (-2.44%)

Closing price 04:00 PM Eastern

Extended Trading

$22.73 +0.32 (+1.41%)

As of 07:32 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Dynavax Technologies NASDAQ:DVAX

$10.72 +0.05 (+0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$10.90 +0.18 (+1.72%)

As of 07:58 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Emergent Biosolutions NYSE:EBS

$6.94 -0.34 (-4.67%)

Closing price 03:59 PM Eastern

Extended Trading

$6.94 +0.00 (+0.07%)

As of 07:34 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Johnson & Johnson NYSE:JNJ

$163.65 +0.67 (+0.41%)

Closing price 03:59 PM Eastern

Extended Trading

$163.84 +0.19 (+0.12%)

As of 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time